Kedalion Capital Management LLP has filed its 13F-HR report, revealing its investment holdings as of September 30, 2026. The firm reported a total value of approximately $4.29 billion in its portfolio. This filing is significant as it provides insights into Kedalion's investment strategy and its positioning within the asset management industry.

Kedalion Capital Management LLP is a London-based investment firm. According to its SEC filings, the firm operates under the entity type of 'other' and has been active in reporting its holdings. The latest filing, dated November 6, 2026, follows a series of 13F-HR submissions, with the previous one filed on August 10, 2026.

The recent filing details the firm's investment in various securities, including notable positions in the SPDR Series Trust and iShares ETFs. For instance, Kedalion holds approximately 44,970,000 shares in the SPDR S&P 500 ETF, valued at around $4.04 billion. Other significant investments include shares in Arbutus Biopharma Corp and Warner Bros Discovery Inc.

The filing also indicates that Kedalion Capital Management has sole investment discretion over its reported holdings, which may influence how competitors and market analysts view the firm's strategies. Companies within the asset management sector may take note of Kedalion's investment choices as they reflect broader market trends and investor sentiment.

As for what’s next, the filing does not specify any upcoming actions or changes. However, the firm’s continued transparency in its investment practices is likely to be closely monitored by industry peers and investors alike.